Lin Sun

Title: Lin Sun: Innovator in Vascular Biology

Introduction

Lin Sun is a prominent inventor based in West Roxbury, MA (US), known for his significant contributions to the field of vascular biology. With a total of 9 patents to his name, he has made remarkable advancements in understanding and manipulating vascular endothelial growth factor receptors (VEGFRs). His work has implications for various therapeutic applications, particularly in inhibiting biological activities mediated by vascular endothelial growth factors (VEGFs).

Latest Patents

Among Lin Sun's latest patents are two notable inventions. The first patent focuses on "Libraries of modified fibronectin type III tenth domain-containing polypeptides." This disclosure relates to novel VEGFR-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by VEGFs. The second patent, titled "Inhibitors of type 2 vascular endothelial growth factor receptors," also centers on VEGFR-binding polypeptides and their applications in inhibiting VEGF-mediated activities. Both patents provide various improvements relating to single domain binding polypeptides.

Career Highlights

Lin Sun has had a distinguished career, working with reputable organizations such as Bristol-Myers Squibb Company and The General Hospital Corporation. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of Lin Sun's notable coworkers include Elena Getmanova and Yan Chen. Their collaborative efforts have further advanced the research and development of innovative solutions in vascular biology.

Conclusion

Lin Sun's contributions to the field of vascular biology through his patents and collaborations highlight his role as a key innovator. His work continues to influence the development of therapeutic strategies targeting vascular endothelial growth factors.